Literature DB >> 10595933

Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

R Horie1, V Gattei, K Ito, S Imajo-Ohmi, T Tange, J Miyauchi, A Pinto, M Degan, A De Iuliis, F Tassan Mazzocco, F M Rossi, M Higashihara, T Watanabe.   

Abstract

We earlier identified a variant of CD30 (CD30v) that retains only the cytoplasmic region of the authentic CD30. This variant is expressed in alveolar macrophages. CD30v can activate the nuclear factor-kappaB (NF-kappaB) as CD30, and its overexpression in HL-60 induced a differentiated phenotype. To better understand the physiological and pathological functions of CD30v, expression of this variant was examined using a multiple approach to examine 238 samples of human malignant myeloid and lymphoid neoplasms. Screening by reverse transcriptase-polymerase chain reaction (RT-PCR) revealed expression of CD30v transcripts in 52 of 72, 7 of 11, 63 of 90, and 7 of 30 samples of acute myeloid leukemia (AML), myeloid blast crisis of myeloproliferative disorders (MBC), and lymphoproliferative disorders (LPDs) of B- and T-cell origin, respectively. CD30v expression was high in monocyte-oriented AMLs (FAB M4 and M5), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma (MM). Using the specific antibody HCD30C2, prepared using a peptide corresponding to the nine amino acids of the amino-terminal CD30v, expression of CD30v protein was detected in 10 of 25 and 2 of 10 AML and ALL samples, respectively. In AMLs, immunocytochemical detection of CD30v revealed the presence of loose clusters of CD30v-expressing cells dispersed amid a population of CD30v-negative blasts. Finally, the parallel expression of CD30v mRNA and protein, as evidenced by Northern and Western blotting, was confirmed in selected cases of AMLs and LPDs. A significant correlation was found between expressions of CD30v and CD30 ligand transcripts in AML and LPD (P = 0.02, odds ratio = 3.2). The association of CD30v with signal-transducing proteins, tumor necrosis factor receptor-associated factor (TRAF) 2, and TRAF5 was demonstrated by coimmunoprecipitation analysis, as was demonstrated for authentic CD30 protein. Expression of transcripts for TRAF1, TRAF2, TRAF3, and TRAF5, as demonstrated by RT-PCR, was noted in leukemic blasts that express CD30v. Collectively, frequent expression of CD30v along with TRAF proteins in human neoplastic cells of myeloid and lymphoid origin provide supportive evidence for biological and possible pathological functions of this protein in the growth and differentiation of a variety of myeloid and lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595933      PMCID: PMC1866953          DOI: 10.1016/S0002-9440(10)65522-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Cross-linking of CD30 induces HIV expression in chronically infected T cells.

Authors:  P Biswas; C A Smith; D Goletti; E C Hardy; R W Jackson; A S Fauci
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

2.  Activation of HIV expression by CD30 triggering in CD4+ T cells from HIV-infected individuals.

Authors:  E Maggi; F Annunziato; R Manetti; R Biagiotti; M G Giudizi; A Ravina; F Almerigogna; N Boiani; M Alderson; S Romagnani
Journal:  Immunity       Date:  1995-08       Impact factor: 31.745

3.  CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity.

Authors:  S Y Lee; S Y Lee; G Kandala; M L Liou; H C Liou; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

4.  A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation.

Authors:  R Horie; S Aizawa; M Nagai; K Ito; M Higashihara; T Ishida; J Inoue; T Watanabe
Journal:  Int Immunol       Date:  1998-02       Impact factor: 4.823

5.  Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines.

Authors:  H J Gruss; N Boiani; D E Williams; R J Armitage; C A Smith; R G Goodwin
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

6.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.

Authors:  C A Smith; H J Gruss; T Davis; D Anderson; T Farrah; E Baker; G R Sutherland; C I Brannan; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

7.  A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages.

Authors:  R Horie; K Ito; M Tatewaki; M Nagai; S Aizawa; M Higashihara; T Ishida; J Inoue; H Takizawa; T Watanabe
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

8.  Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.

Authors:  H Dürkop; U Latza; M Hummel; F Eitelbach; B Seed; H Stein
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

9.  TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling.

Authors:  T K Ishida; T Tojo; T Aoki; N Kobayashi; T Ohishi; T Watanabe; T Yamamoto; J Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Antibodies specific for proteolyzed forms of protein kinase C alpha.

Authors:  H Kikuchi; S Imajoh-Ohmi
Journal:  Biochim Biophys Acta       Date:  1995-11-30
View more
  4 in total

1.  Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells.

Authors:  A Cerutti; A Schaffer; R G Goodwin; S Shah; H Zan; S Ely; P Casali
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  TRAF2 recruitment via T61 in CD30 drives NFκB activation and enhances hESC survival and proliferation.

Authors:  Nilay Y Thakar; Dmitry A Ovchinnikov; Marcus L Hastie; Bostjan Kobe; Jeffrey J Gorman; Ernst J Wolvetang
Journal:  Mol Biol Cell       Date:  2015-01-07       Impact factor: 4.138

3.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24

Review 4.  Genetic Alterations of TRAF Proteins in Human Cancers.

Authors:  Sining Zhu; Juan Jin; Samantha Gokhale; Angeli M Lu; Haiyan Shan; Jianjun Feng; Ping Xie
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.